配对风险评分预测急性冠脉综合征后28天至1年的缺血与出血风险
该研究基于新西兰ACS质量改善登记库,开发了针对出院后28天至1年时间窗的配对缺血与出血风险评分。两评分校准良好,区分度中等,可辅助临床决策DAPT时程。
要点
- 配对评分分别预测缺血事件和出血事件,辅助个体化DAPT时程决策。
- 缺血评分Harrell C指数0.75,出血评分0.69,校准良好。
- 按2020 ESC算法,31%高危出血且高危缺血患者可考虑缩短DAPT。
核心结论
- 配对缺血与出血风险评分可辅助临床医生和患者在ACS后第一个月之后决定DAPT时程。
研究设计与样本
- 基于新西兰All NZ ACS Quality Improvement登记库,纳入2012-2020年18-84岁、出院后28天无事件且无房颤的ACS患者,开发两个多变量风险预测评分。
主要发现
- 应用2020 ESC ACS抗栓治疗算法,31%的患者出血和缺血风险均升高(>2%),可考虑缩短DAPT时程。
- 低出血风险但缺血风险升高的患者占37%,可能适合延长DAPT;低出血且低缺血风险的患者占29%,短DAPT可能合理。
关键数值与推荐
- 缺血评分预测心血管死亡/心梗再住院或缺血性卒中再住院;出血评分预测出血死亡/出血再住院。
- 出血和缺血风险均>2%视为升高,对应队列31%的患者。
临床怎么用
- 临床可利用配对评分评估ACS出院后28天至1年的缺血与出血风险,结合2020 ESC算法个体化决定DAPT时程。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The recommended duration of dual anti-platelet therapy (DAPT) following acute coronary syndrome (ACS) varies from 1 month to 1 year depending on the balance of risks of ischaemia and major bleeding. We designed paired ischaemic and major bleeding risk scores to inform this decision. METHODS: New Zealand (NZ) patients with ACS investigated with coronary angiography are recorded in the All NZ ACS Quality Improvement registry and linked to national health datasets. Patients were aged 18-84 years (2012-2020), event free at 28 days postdischarge and without atrial fibrillation. Two 28-day to 1-year postdischarge multivariable risk prediction scores were developed: (1) cardiovascular mortality/rehospitalisation with myocardial infarction or ischaemic stroke (ischaemic score) and (2) bleeding mortality/rehospitalisation with bleeding (bleeding score). FINDINGS: In 27 755 patients, there were 1200 (4.3%) ischaemic and 548 (2.0%) major bleeding events. Both scores were well calibrated with moderate discrimination performance (Harrell's c-statistic 0.75 (95% CI, 0.74 to 0.77) and 0.69 (95% CI, 0.67 to 0 .71), respectively). Applying these scores to the 2020 European Society of Cardiology ACS antithrombotic treatment algorithm, the 31% of the cohort at elevated (>2%) bleeding and ischaemic risk would be considered for an abbreviated DAPT duration. For those at low bleeding risk, but elevated ischaemic risk (37% of the cohort), prolonged DAPT may be appropriate, and for those with low bleeding and ischaemic risk (29% of the cohort) short duration DAPT may be justified. CONCLUSION: We present a pair of ischaemic and bleeding risk scores specifically to assist clinicians and their patients in deciding on DAPT duration beyond the first month post-ACS.
引用
- Kerr, Choi, Williams, et al. Paired risk scores to predict ischaemic and bleeding risk twenty-eight days to one year after an acute coronary syndrome. Heart. 2023. PMID: 37558394. doi:10.1136/heartjnl-2023-322830
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。